Alexion Pharmaceuticals Inc (ALXN) Posts Q3 EPS of $0.29, Beats By 8c; Guides
More News related to ALXN
- Alexion to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of Patients With PNH at the ASH Annual Meeting
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
- Alexion to Present at Credit Suisse's 2009 Healthcare Conference
- Bank of America Initiates Coverage on Alexion Pharmaceuticals (ALXN) with a Neutral
More News related to Earnings
- Afternoon ETF Check: SMH Up; XLF, TAN, EWJ Down
- Unusual 11 Mid-Day Movers 11/24: IWA, DRAM, ABG, TIXC Higher; WH, WMG, ABIO, NYNY Lower
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
- Notable Mergers and Acquisitions of the Day 11/24: WIN/IWA, GMCR/DDRX, PLA
- Morning Movers 11/24: IWA, SEED, FEED, AEZS Higher; WH, ORS, ABIO, GRO, LONG Lower
Alexion Pharmaceuticals Inc (NYSE: ALXN) reports Q3 EPS of $0.29, 8 cents better than the analyst estimate of $0.21. Revenue for the quarter was $102.63 million, which compares to the estimate of $98.03 million.
Sees FY09 non-GAAP EPS of $1.15 - $1.18, from $1.01 - $1.05.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.81Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
